Drug Trial Radar · NCT01339260
An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
Last checked: Nov 20, 2026Latest source record: Nov 26, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,455
Actual
Start
Apr 2011
Primary completion
Nov 2012
Sponsor
- Lead sponsor
- Helsinn Healthcare SAIndustry
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Apr 20, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone. The objective of the study is to demonstrate that netupitant and palonosetron are more effective than palonosetron alone, to prevent nausea and vomiting induced by moderately emetogenic cancer chemotherapy after administration of repeated cycles of chemotherapy.
Conditions
- Chemotherapy-Induced Nausea and Vomiting
Interventions
Netupitant and PalonosetronDrug
PalonosetronDrug
DexamethasoneDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, at Cycle 1Time frame: 25-120 hours
Locations
172 sites in 15 countries. Site status is shown where the registry gives one.
Anniston Oncology/Regional Medical Center
Anniston, Alabama
Northwest Alabama Cancer Center
Muscle Shoals, Alabama
Genesis Cancer Centre
Hot Springs, Arkansas
Compassionate Cancer Care Medical Group Inc
Corona, California
Compassionate Cancer Centre Medical Group
Fountain Valley, California
American Institute of Research
Los Angeles, California
Facey Medical Group
Mission Hills, California
Compassionate Cancer Care Medical Group
Riverside, California
American Institute of Research
Whittier, California
Denver Health and Hospital Authority
Denver, Colorado
Palm Beach Institute of Hematology and Oncology
Boynton Beach, Florida
Baptist Cancer Institute
Jacksonville, Florida
Deaconess Clinic Downtown
Evansville, Indiana
Floyd Memorial Cancer Center of Indiana
New Albany, Indiana
Kentucky Cancer Clinic
Hazard, Kentucky
The John R Marsh Cancer Center
Hagerstown, Maryland
Fallon Clinic at Worcester Medical Center
Worcester, Massachusetts
Duke University Medical Center
Durham, North Carolina
Piedmont Hematology Oncology Associates PA
Winston-Salem, North Carolina
Tri-County Hematology and Oncolgy Associates Inc.
Massillon, Ohio
Signal Point Clinical Research Center LLC
Middletown, Ohio
Charleston Cancer Center
Charleston, South Carolina
Charleston Hematology Oncology
Charleston, South Carolina
Wellmont Medical Associates-Oncology and Hematology
Bristol, Tennessee
Cancer Specialists of South Texas, P.A.
Corpus Christi, Texas
The University of Texas Health Center
Tyler, Texas
Northern Utah Associates Hematology / Oncology
Ogden, Utah
Northwest Medical Specialties
Tacoma, Washington
Hospital Italiano de Cordoba
Córdoba, Argentina
Clínica Universitaria Reina Fabiola (Universidad Católica de Córdoba)
Córdoba, Argentina
Instituto Oncológico de Córdoba - Sanatorio Aconcagua
Córdoba, Argentina
Centro Oncológico Integral (COI)
Mar del Plata, Argentina
Centro Oncologico de Integracion Regional (COIR)
Mendoza, Argentina
Instituto Médico CER [Oncology]
Quilmes, Argentina
Sanatorio Parque
Rosario, Argentina
Centro Medico San Roque
San Miguel de Tucumán, Argentina
ISIS Clinica Especializada
Santa Fe, Argentina
Bobruisk Interregional Oncological Dispensary
Babruysk, Belarus
Brest Regional Oncological Dispensary
Brest, Belarus
Gomel Regional Clinical Oncological Dispensary
Brest, Belarus
Showing 40 of 172 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.